Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shaughnessy JO"'
Publikováno v:
Human Genomics, Vol 5, Iss 6, Pp 703-708 (2011)
Abstract Many primary biological databases are dedicated to providing annotation for a specific type of biological molecule such as a clone, transcript, gene or protein, but often with limited cross-references. Therefore, enhanced mapping is required
Externí odkaz:
https://doaj.org/article/967f113d76b64dfbbae41a206e9a7861
Autor:
Zhao Chen, Shi Leming, Tong Weida, Shaughnessy John D, Oberthuer André, Pusztai Lajos, Deng Youping, Symmans W Fraser, Shi Tieliu
Publikováno v:
BMC Genomics, Vol 12, Iss Suppl 5, p S3 (2011)
Abstract Background Microarray data have been used for gene signature selection to predict clinical outcomes. Many studies have attempted to identify factors that affect models' performance with only little success. Fine-tuning of model parameters an
Externí odkaz:
https://doaj.org/article/d3c8dfa93aac477ba7970c1def52a214
Autor:
Zhan Fenghuang, Woo Hyun Goo, Lee Ju-Seog, Wang Hongyang, Gupta Shalu, Shaughnessy John D, Park Eun Sung, Owens James D, Potter Michael, Janz Siegfried, Mushinski J Frederic
Publikováno v:
BMC Genomics, Vol 8, Iss 1, p 302 (2007)
Abstract Background To elucidate the genes involved in the neoplastic transformation of B cells, global gene expression profiles were generated using Affymetrix U74Av2 microarrays, containing 12,488 genes, for four different groups of mouse B-cell ly
Externí odkaz:
https://doaj.org/article/f2b2fbb8b9e847fabac5a5c84ff20503
Autor:
Hanamura Ichiro, Zhan Fenghuang, Zingone Adriana, Raducha-Grace Laura, Peterson Timothy R, Dib Amel, Barlogie Bart, Shaughnessy John, Kuehl W Michael
Publikováno v:
Cell Division, Vol 1, Iss 1, p 23 (2006)
Abstract Background A high proliferative capacity of tumor cells usually is associated with shortened patient survival. Disruption of the RB pathway, which is critically involved in regulating the G1 to S cell cycle transition, is a frequent target o
Externí odkaz:
https://doaj.org/article/013c7e16ce8140938d2966a67a999659
Autor:
Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Loirat D; Institut Curie, Paris, France., Punie K; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Oliveira M; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Brufsky A; Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA., Kalinsky K; Winship Cancer Institute, Emory University, Atlanta, GA., Cortés J; International Breast Cancer Center, Quiron Group, Barcelona, Spain., Shaughnessy JO; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX., Diéras V; Centre Eugène Marquis, Rennes, France., Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Gianni L; Gianni Bonadonna Foundation, Milan, Italy., Piccart-Gebhart M; Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium., Loibl S; Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany., Yoon OK; Gilead Sciences, Inc, Foster City, CA., Pan Y; Gilead Sciences, Inc, Foster City, CA., Hofsess S; Gilead Sciences, Inc, Morris Plains, NJ., Phan SC; Gilead Sciences, Inc, Foster City, CA., Hurvitz SA; Division of Hematology and Oncology, Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 20; Vol. 42 (15), pp. 1738-1744. Date of Electronic Publication: 2024 Feb 29.